HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislation Adding SARMs to CSA Schedule III Introduced In Senate

Executive Summary

“By placing SARMs on the same schedule as other anabolic steroid, we’re ensuring a safer and more transparent marketplace," says Iowa Republica Chuck Grassley, who sponsored the bill with Rhode Island Democrat Sheldon Whitehouse.

You may also be interested in...



Massachusetts Bid Stalls To Age-Restrict Sales Of Bodybuilding, Weight Loss Supplements

"We spent a lot of time in Massachusetts trying to point out the flaws in the legislation," says CRN government relations chief Mike Greene. CRN and other stakeholders could focus on the Massachusetts bill because no other similar proposals surfaced in other state legislatures this year.

SARMs Subject To Steroids Scheduling By DEA Under Hatch, Whitehouse Bill

The Utah Republican and Rhode Island Democrat sponsor legislation to make selective androgen receptor modulators subject to the same authority the Drug Enforcement Administration has to regulate anabolic steroids. Hatch said the SARMs Control Act of 2018 would "ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”

Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026

Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.

Topics

UsernamePublicRestriction

Register

RS149447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel